Join to View Full Profile
UK Medical Oncology800 Rose Street CC401 Roach BuildingLexington, KY 40536
Phone+1 859-323-6522
Fax+1 859-257-3757
Dr. Villano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1999 - 2001
University of MichiganResidency, Neurology, 1998 - 1999
University of Texas Southwestern Medical SchoolClass of 1997
Certifications & Licensure
KY State Medical License 2011 - 2026
FL State Medical License 2015 - 2017
IL State Medical License 1999 - 2017
MI State Medical License 1998 - 1999
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
- Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
- Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Start of enrollment: 2012 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.Alexia Shamaei Zadeh, Danielle Roberts, Abby Williams, Deepali Pandey, John L Villano
Cancer Chemotherapy and Pharmacology. 2025-01-18 - Outcomes of Brain Metastasis from Lung Cancer.James M Mobley, Kerry I Phillips, Quan Chen, Ellen Reusch, Niharika Reddy
Cancers. 2025-01-14 - 2 citationsA First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.Olivier Rixe, John L Villano, Robert Wesolowski, Anne M Noonan, Vinay K Puduvalli
Clinical Cancer Research. 2024-11-15
Press Mentions
Ky. Attorney Defies Brain Cancer Odds Through Markey Clinical TrialMay 15th, 2025- Brain Cancer Awareness: Understanding the Signs, Risks and TreatmentsMay 5th, 2025
Phase 1b Trial of Proteasome Inhibitor Carfilzomib with Irinotecan in Lung Cancer and Other Irinotecan-Sensitive Malignancies That Have Progressed on Prior Therapy (Onyx IST Reference Number: CAR-IST-553)February 16th, 2020- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
